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Abstract
The purpose of this research was to (a) examine the demographics of patients receiving
care in an outpatient cardiology clinic, (b) describe the relationship between the atrial fibrillation
(AF) and other variables (e.g., BMI), (c) examine the frequency and the length of time to AF
diagnosis in patients implanted with an implantable cardiac monitoring (ICM) device, (d)
observe provider patterns of treatment with oral anticoagulants (OACs), and (e) investigate
documented considerations to either diagnose or rule out OSA in a group of outpatient AF
patients in a cardiology clinic.
Background: AF is largely undiagnosed but can cause major morbidity and mortality. AF is
the most prevalent sustained arrhythmia encountered in the emergency department, is frequently
detected in those without a prior diagnosis of AF, and is the most common cause for stroke. All
relevant guidelines suggest patients from intermediate to high risk for stroke should receive
OAC; however, this therapy is prescribed in less than 55% of eligible patients. AF accounts for
nearly 1 in 7 strokes and affects approximately 5.8 million people in the United States.
Objectives: The purpose of this study is to identify and intervene in patients with atrial
fibrillation using an implantable cardiac monitor to significantly improve guideline-based
anticoagulation therapy.
Methods: A retrospective database from an outpatient clinic in southern California was
analyzed in this non-experimental study design; it comprised routinely-collected data on patients
with ICMs implanted between June 1, 2014 and December 31, 2018. This study was designed to
establish the incidence of AF using an ICM device (i.e., Medtronic LINQ) in the outpatient
setting.

Conclusions: As evidenced by this study, most patients would not have been diagnosed with AF
utilizing the shorter-duration monitoring devices typically used as the first line of treatment.
Longer monitoring capabilities promise early identification of disease and reduction in morbidity
for AF patients.
Discussion: The incidence of AF using an ICM (i.e., Medtronic LINQ) device in an outpatient
clinic was 23.4% (63 out of 269 patients), similar to national studies stating that longer
monitoring of cardiac rhythms increased the diagnosis of arrythmias. Only 12.7% of detected
AFs (11 out of 63 patients) occurred before 14 days, the maximum time available through the
use of other, traditional monitoring devices in standard use; therefore, an alarming 87.3% of
ICM-detected arrythmias could have remained unidentified. This research observed a reduction
of potential, highly-debilitating embolic stroke through detection as well as a lessened risk of allcause mortality with OACs for AF patients without stroke prophylaxis; early identification and
treatment is possible utilizing an ICM device.
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Chapter 1
Statement of the Problem
The purpose of this study is to identify and to provide early intervention with patients at
high risk for nonvalvular atrial fibrillation (AF) with implantable cardiac monitoring devices
(ICM) and significantly improve treatment with guideline-based oral anticoagulation (OAC). AF
affects 1% to 2% of the general population and the prevalence is increasing worldwide, due in
part to the aging population (Colilla, Crow, Petkun, Singer, Simon, & Liu, 2013). This number
is estimated to double by 2050 (Miyasaka, Barnes, & Gersh, 2006). The cost of care for patients
with AF are substantial. Estimates range from $6 billion to $26 billion a year of which $6 billion
was attributed directly to AF and $9.9 billion to other cardiovascular expenses (Mozaffarian,
Benjamin, & Go, 2015). AF is often asymptomatic, paroxysmal, or both (Barbarossa, Guerra, &
Capucci, 2014); therefore, the arrythmia goes undetected until major complications arise and/or
patients become disabled. In some cases, the diagnosis of thromboembolism/ stroke may be the
first identification of AF. AF is associated with a four- to five-fold increase in risk for
thromboembolism (Wolf, Abbott, & Kannel, 1991). Thromboembolism/stroke is a leading cause
of long-term disability and can lead to irreversible harm such as memory loss, altered
psychological status, speech/language difficulty, and disability/paralysis (Mozaffarian et al.,
2015). Early identification and treatment of patients with AF are essential in decreasing
devasting effects from thromboembolic disease. With the Internet, smart phones, and other new
ways of detection, AF can be identified more frequently, but currently there are no protocols or
guidelines to diagnosis this elusive arrythmia. The inability to provide timely identification or
diagnosis of AF is imperative and supports the purpose of this research study. The goal of this
research project is to determine the most specific and accurate method(s) for the early

identification of AF; newer forms of detection have inaccurately provided noise where they are
typically a warning and a way for further investigation by a licensed practitioner. When AF is
symptomatic, detection is straightforward because the symptoms often include palpitations,
syncope, chest pain, or shortness of breath. These symptomatic cases are typically diagnosed
and treated quickly due to the patient’s ailing complaints and presentation to the health care
practitioner. Nonetheless, AF is most often asymptomatic and therefore is largely undiagnosed
until the occurrence of major morbidity or mortality through thromboembolism or heart failure
(HF). Improved guideline-based therapy could directly reduce the risk of a potential, highly
debilitating thromboembolism in AF patients.
This study will commence with a description of the scope and significance of AF. A
discussion ensues for more timely identification of AF with ICM and approaches for continued
follow up for patients with AF. These sections will be followed by a review of the literature that
support the rationale for this study.
Background and Significance
The purpose of this research is to add knowledge to the early detection of AF and to
assist in decreasing morbidity and mortality and advancing timelier treatment of AF with oral
anticoagulants, procedures, and treatments using ICMs to identify arrythmias. Currently, no
protocols or guidelines exist on the diagnosis of AF or the type of monitoring device to use.
Presently, the provider selects the monitoring device based on comfort and knowledge of the
products. Monitors vary in duration of surveillance for cardiac rhythms, from seconds up to 3
years. As the population ages, the prevalence of AF increases as does the sequela of AF’s
morbidity and mortality effects. The U.S. population aged 65 years and over grew from 35.0
million in the year 2000 to 49.2 million in the year 2016; expectations are for continued growth

in this population sector (U.S. Census Bureau, 2017). The median age in the United States is
expected to grow from 38 years old today to 43 years old by 2060 (U.S. Census Bureau, 2018).
AF is the most prevalent sustained arrythmia encountered in emergency departments
(EDs) and outpatient clinics; 3.6% to 7.0% of general emergency visit (Coll-Vinent, Malagon et
al., 2007). Currently there is no implementation of common guidelines at various care levels to
improve AF treatment (Coll-Vincent, Pacheco et al., 2007). AF is defined by the American
Heart Association as a heart arrythmia where the upper chambers of the heart (the atria) beat
irregularly instead of beating effectively to move blood into the ventricles (American Heart
Association, n.d.). AF can decrease the heart’s pumping capacity by as much as 30% (Harvard
Medical Publications, 2018). When blood does not move effectively, it can become stagnant and
thickened to form thrombus (i.e., clot) that could lead to dangerous thromboembolic events. The
blood cells adhere to each other and form clots in the left atrial appendage (LAA) of the heart
(Blackshear, & Odell, 1996). When the thrombus escapes from the LAA, it then can travel to
other areas of the body, cut off blood supply, and cause a stroke (Cleveland Clinic, n.d.). AF can
be persistent, paroxysmal, or permanent. Persistent AF lasts longer than 1 week. The arrythmia
may stop on its own or require medical therapy. Paroxysmal/intermittent AF is spontaneously
and terminates in less than 7 days. Permanent AF continues and cannot be corrected. AF may
be symptomatic, but is often asymptomatic. Up to one-third of all individuals with AF may not
be aware of their condition (Steinhubl, Waalen, Edwards, Mehta et al., 2017). Symptomatic AF
is often described as palpations, syncope, chest discomfort, fatigue, and shortness of breath.
Symptomatic AF is favorable because it can be detected and treated more efficiently.
Asymptomatic AF is usually identified after having an embolic event, positive random ECG, or
HF exacerbation; therefore, the disease is challenging to diagnosis and treat. The correlation

between symptoms and AF is unreliable for disease recognition. Patients with AF typically have
other cardiovascular comorbidities (e.g., HF, obstructive sleep apnea [OSA]). These patients are
at elevated risk of cardiovascular and thromboembolic events and mortality when compared with
non-AF patients (Benjamin et al., 1998). Patients with AF are 5 times more likely to have a
stroke than those who do not have AF (National Stroke Association. n.d.). The purpose of
researching ICM and AF detection is to identify patients with AF earlier, increase treatment rates
per guidelines, and increase knowledge by having constant electrocardiogram (ECG) capability.
A study by Ziegler, Koehler, and Mehra (2006) demonstrated that extending the monitoring
duration from 24 hours to 7 days significantly increased the AF detection rate. Additionally,
according to Brignole et al. (2004), subcutaneous implantable monitors were largely accepted in
clinical practice for diagnosing patients with unexplained syncope. Providers have a wealth of
mechanisms when selecting a monitoring technique. The options vary from 48-hour Holter
monitors, 3- to 7-day telemetry monitors, watches, 7-day patches, and implantable devices. The
time needed to detect AF is still unknown; however, a recent CRYSTAL AF study reported 84126 days was needed on average (Sanna et al., 2014). Providers are utilizing a haphazard
approach in monitoring patients; therefore, are unable to identify an AF diagnosis. The ICM
could potentially help guide individual patient treatment (Lim, & Lip, 2008).
Asymptomatic AF has major implications for society, can challenge national health care
costs, and can require extra services post disease state. The current mainstay in treatment for AF
is anticoagulation, but other treatment modalities offer promising results, including intervention
approaches (e.g., Watchman device, left atrium clip). Diagnosis at older ages and/or with
increased morbidity burden U.S. health care costs. For AF-verses-control subjects, the mean
annual inpatient cost-per-patient were $7,841 verses $2,622, outpatient medical costs were

$9,225 versus $5,629, and outpatient pharmacy costs were $3,605 versus $3,714 (Benjamin et
al., 1998). The total incremental costs for AF were $8,705 per patient; the national incremental
costs for AF were $26 billion (Benjamin et al., 1998).
HF is a devastating outcome of AF; a chronic disease that must be managed with strict
diet and daily medications. HF develops in as many as 40% of patients with AF (Schnabel et al.
2013; Wang et al., 2003). Among patients aged between 55-74 years, the 10-year mortality was
61.5% in men with AF compared to 30% in men without AF. Among women in similar age
group, the 10-year mortality was 57.6%, in the AF group verses 20.9% in women without AF
(Stewart, Hart, Hale, & McMurray, 2002). HF affects approximately 4.8 million people in the
United States and Americans are spending over $17 billion annually on treatments for HF
(American Heart Association, n.d.). Patients are often readmitted to the hospital for HF
exacerbation due to the difficulty in managing this disease.
Treatment for AF typically includes rate control, rhythm control, and embolic stroke risk
protection with OAC. In patients with AF, 85%-90% may be candidates for OAC therapy
(Freeman et al., 2015). Treatment for AF begins with risk stratification of the embolic
probability and calculated risk stratification score; an anticoagulant is prescribed depending on
the guidelines. Risk stratification involves assessing every patient for key elements, such as
Congestive heart failure, Hypertension, Age, Diabetes, history of TIA or Stroke, Vascular
disease, Age (again), and female Sex (CHA2DS2-VASc). Each element contributes 1 or 2 points;
a total score of 2 or greater indicates that the patient should be prescribed an OAC. The higher
the CHA2DS2-VASc risk score, the higher the embolic risk. Often patients do well on OAC
(e.g., Xarelto, Eliquis, coumadin); however, patients must understand the bleeding risks verses
the embolic risk when taking OACs. The bleeding risk often creates a dilemma with clinician

prescribing habits; the need to evaluate the risk of bleeding versus possible legal action. In the
United States, multiple lawsuits have been filed alleging harm from blood thinners.
Research Aims
This research study examined data using the following study aims:
AIM 1: Describe the patient demographics (e.g., age, gender, ethnicity, AF) of patients receiving
care in an outpatient cardiology clinic.
AIM 2: Describe the relationship between the dependent variable (AF) and independent
variables (e.g., BMI) in patients receiving care in an outpatient cardiology clinic.
AIM 3: Examine the frequency of AF diagnosis and the length of time to diagnosis in patients
implanted with an ICM receiving care in an outpatient cardiology clinic.
AIM 4: Examine provider patterns of treatment with OACs.
AIM 5: Investigate documented considerations to diagnose or rule out OSA in a group of
outpatient AF patients in a cardiology clinic.

Chapter 2
Review of the Literature
The purpose of this chapter is to summarize the current literature about AF with
comprehensive literature search using Cumulative Index to Nursing Allied Health Literature
(CINAHL), Google Scholar, Ovid SP, PubMed, Cochrane database and evidence-based medical
reviews and current literature in nationally recognized journals. Key search terms were AF,
cardiac monitors, cardioembolic events, and related terms. Additional articles from the reference
sections were used from cited articles. AF is largely undiagnosed and can cause major morbidity
and mortality. AF is the most common cause for stroke (Aguilar & Hart, 2008). Of those
patients with AF, their average yearly risk for stroke is 5%, and the risk is increased in the
presence of certain risk factors, including left ventricular dysfunction, hypertension, increasing
age, and history of stroke (Atrial fibrillation Investigators 1994) and now has increased with the
addition of risk factors such as diabetes, gender, CAD, renal impairment, sleep apnea or chronic
obstructive pulmonary disease and vascular history. These are independent risk factors
associated with increased stroke risk. (Mozaffarian, Benjamin, GO et al…) AF is the most
prevalent sustained arrhythmia encountered in the emergency department (ED) and outpatient
clinic and is frequently detected in those without a prior diagnosis of AF (Coll-Vinent, Martin,
Malagon, & HERMES-F Investigators, 2015).
As the population ages, the risk for stroke increases (Mozaffarian et al., 2016). The
population is living longer therefore the age that providers see to treat becomes older and
treatment is longer. That is nearly 3 to 6 million people in the United States (Go et al., 2001).
All relevant guidelines suggest patients that are intermediate to high risk for stroke
should receive OAC (Stiell, & Macle, 2010). Anticoagulation with warfarin was once the only

choice but now there are novel oral anticoagulants that provide better cover and less interactions
for patients. When prescribing oral anticoagulants, the clinician balances the risk for bleeding
and the risk for stroke in each patient individually. Based on those risk the clinicians can pick
from the variety of anticoagulants based on compliance, bleeding risk, availability and cost
among other preferences. Warfarin is often affected by the foods eaten or other medications
prescribed or over the counter. International ratio blood work is also needed regularly to monitor
therapeutic levels while on warfarin. With the new novel oral anticoagulants, patients are not
restricted to a particular diet and do not have to monitor blood work while taking the OACS.
Although anticoagulation is the goal in stroke prevention, often anticoagulation is not prescribed
and if it is prescribed, the patients stopped taking the medication at 50% after 2 years
(PINNACLE Registry Aug 2016). Currently, anticoagulation is prescribed in less than 55% of
eligible patients (Lane & Lip, 2012). Forty percent of patients that were intermediate to high risk
for stroke were under treated by receiving aspirin only (PINNACLE Registry Aug 2016). AF
accounts for nearly 1 in 7 strokes (Roldán et al. 2013) and affects about 5.8 million people in the
United States (Colilla et al., 2012). Therefore, the diagnosis is hard to identify and then, if the
patient is diagnosed, appropriate treatment occurs less than 50% of the time. Documentation is
key to supporting an accurate diagnosis. AF results in a five times greater risk of stroke and
approximately 15% of strokes are due to AF (Wolf Abbott, & Kannel, 1991). ICMs play a
substantial role as a safety net for the management of AF. Identifying AF is critical for guiding
preventative therapy decisions. We now have ICMs that can continuously monitor patients for
several years and detect episodes of asymptomatic AF that are as brief as a few seconds. (Sanna,
Diener, Passman et al 2014). These monitors could assist in early diagnosis and identification of
with followed treatment.

The Cryptogenic Stroke and Underlying Atrial Fibrillation study (CRYSTAL AF)
assessed whether long term monitoring with an ICM was superior to standard monitoring for the
detection of AF in patients with cryptogenic stroke at 6 months and 12 months. This study also
looked at providers actions post diagnosis of AF. AF is defined as an irregular heart rhythm for
more than 30 seconds without detectable p waves. The researchers found 6.4 times more
patients to have AF over 6 months using ICM. They also noted the median time to AF detection
was 84 days. After the diagnosis of AF, the majority (97%) who had AF were prescribed OACs.
In support of longer monitoring, the REVEAL AF was a prospective study of previously
undiagnosed AF as documented by an ICM in high-risk patients (Reiffel et al. 2017). AF is
often silent and considered subclinical, therefore goes undetected until major morbidity and
mortality occurs. Recent studies showed AF and symptoms that only 13% to 21 % of episodes
with symptoms suggestive of AF reported by patients with implanted pacemakers were AF
episodes according to the pacemaker log. (Quirino at el., 2009).
Use of intracardiac monitoring provides the clinician with daily ECGs for evaluation of
arrythmias for longer periods of time. Research on their use in the outpatient clinic setting is
more limited. In a recent abstract present at American College of cardiology, even the ECG
patch found 9 times more AF than conventual means of monitoring. They stated that the ECG
patch had 5.1% rate of new AF diagnoses compared the usual controls at 0.6%. These
researchers defined high risk patients as those 75 years or older, or at least 55 years old and male
or 65 years old and female. Those younger than 75 years old had to have a least one risk factor
such as prior cerebral vascular event, heart failure, hypertension plus diabetes, or OSA.
(Steinhubl, 2018).

Risk factors such as congestive heart failure, hypertension, age, diabetes, history of TIA
or stroke, vascular disease, and female gender have been identified and studied to increase
embolic risk in patients with AF. OSA is a popular topic in current literature as another possible,
pertinent risk factor for patients with AF that increases embolic risk. OSA is defined as a sleep
disorder characterized by partial or complete obstruction of the airway due to the collapse of
pharyngeal muscles, leading to the reduction of airflow (hypopnea) or complete absence of
airflow (apnea; Mannarino, Di Filippo, and Pirro, 2012). Sleep apnea is diagnosed when a
patient experiences five or more episodes of hypopnea or apnea per hour during sleep along with
associated symptoms, such as daytime sleepiness (Mannarino et al., 2012). OSA has been linked
to increase mortality and morbidity and associated with cardiac arrythmias, heart failure, and
stroke (Butt, Dwivedi, Khair, and Lip, 2010).
The STOP-BANG questionnaire is a valid and reliable tool to determine patients who are
at risk for sleep apnea. The questionnaire uses subjective and objective data points to calculate a
risk score. The screening tool assesses for snoring, tired, observed, body mass index >35kg/m2,
age >50 years old, neck circumference >16 inches (41 cm), and male gender. Scores are
calculated as low risk (yes to 0-2 questions), intermediate risk (yes to 3-4 questions) and high
risk (yes to 5-8 questions, or yes to 2 or more of 4 STOP questions and male gender, or yes to 2
or more of 4 STOP questions and BMI > 35 kg/m2, or yes to 2 or more of 4 STOP
questions and neck circumference ≥ 17 inches [43 cm] in males or 16
inches [41 cm] in females). A research AIM in this study examines
patients who have OSA; these patients also have up to four times the
risk of developing AF when compared to patients without OSA (Anter
et al., 2017). This study will test an innovative approach through the

use of ICM to assure that newly-diagnosed AF patients in an
outpatient clinic are diagnosed early and risk-stratified with a
therapeutic plan for OAC, if applicable. A cardiologist and
cardiology nurse practitioner will use ICM data to improve the
diagnosis of AF patients with prescribed stroke prophylaxis.
Intracardiac monitoring is a novel and an innovative approach to
providing a safety net for AF patients diagnosed in the outpatient
clinic.

Chapter 3
Methods
The purpose of this research will add to the information on detecting AF earlier and assist
in decreasing major morbidity and mortality by identifying AF earlier and treating with oral
anticoagulants or procedures/treatments using ICMs to identify arrythmias. This research will
also investigate considerations for OSA in patients with AF.
Study Design
A retrospective database from an outpatient clinic in southern California was analyzed in
this non-experimental study design; it comprised routinely-collected data on patients with an
ICM implanted between June 3, 2014 and December 27, 2018. This study was designed to
establish the incidence of AF using an ICM device (i.e., Medtronic LINQ) in the outpatient
setting. To protect human subjects, Institutional Review Board approval was obtained from the
University of San Diego. Study limitations were also addressed. All patients who received ICM
devices from June 2014 through December 2018 in one outpatient cardiology clinic comprised
this study population. The non-experimental design was appropriate for this study to assess
relationships among variables. Patients initial demographics, diagnosis of AF, number of days
from implant to AF event, implant justification, intervention with OACs, and assessment of sleep
apnea risk were recorded and analyzed. Once the diagnosis of AF was determined, a cardiology
nurse practitioner calculated embolic and bleeding-risk assessment scores for each patient.
In accordance with the 2014 ACC/AHA/ESC AF practice guidelines concerning patients
with AF, the CHA2DS2-VASc score has been recommended to assess for stroke risk (January et
al. 2014). The CHA2DS2-VASc (i.e., Congestive heart failure history, Hypertension history, Age
> 75, Diabetes mellitus history, previous Stroke or TIA symptoms, Age 65-74, Vascular disease

history, and [female] Sex) is a risk-stratification tool that offers a comprehensive measurement
(percentage) of a patient’s risk for an embolic event over the next year (Lip et al. 2010). This
tool is commonly used to determine guideline-based usage and prescriptions of OACs .The
HAS-BLED (i.e., Hypertension, Abnormal renal/liver function, Stroke, Bleeding history or
predisposition, Liable INR, Elderly, Drugs/alcohol) is another score that is recommended by the
European and Canadian AF guidelines to estimate the risk for bleeding in anticoagulated and
standard patients over the next year (Roldán et al. 2013). If the risk score utilizing the
CHA2DS2-VASc is greater than 2 or the HAS-BLED score is less than 3, the patient is deemed
appropriate for a prescribed OAC after risk and benefits have been discussed with the patient.
Over estimation of bleeding risk is a significant barrier in prescribing OAC, especially among
elderly patients (Lane & Lip 2013). Elderly patients are often thought to be at a higher risk of
bleeding as well as a fall risk. To the contrary, these patients tend to be undertreated and are
often times at a higher embolic risk due to increased age. These risk management scores enabled
the clinician to assess the most appropriate antithrombotic therapy for stroke prophylaxis in nonvalvular AF.
Sampling Procedures/Setting
The study population included all patients in one southern California, outpatient
cardiology clinic who had been implanted with the Medtronic LINQ. Patients without a history
of AF but experiencing symptoms of palpitations, syncope, cryptogenic stroke, or suspected AF
were enrolled.
Measures
Data were collected on patients with CHA2DS2-VASc scores of ranging from 0 to 10
with two risk factors (e.g., CAD, renal impairment, sleep apnea). Data were accessed and

obtained from the patient’s electronic medical records and the Medtronic LINQ Carelink
database utilizing a standardized data collection form. This data form was then transferred into a
password-protected Excel file for validation, auditing, and summarization. The assessment tools,
CHA2DS2-VASc and HAS-BLED, have been statistically validated in research studies.
CHA2DS2VASc has a pooled C statistic of 0.667 (95% CI [0.651, 0.683]) for patients taking
anticoagulation therapy and 0.675 (95% CI [0.656, 0.694]) for non-anticoagulation patients
(Chen et al. 2013). HAS-BLED demonstrated accuracy at predicting the risk of major bleeding
(C statistic, 0.69, 95% CI [0.67, 0.72; Roldán et al., 2013). Categorical variables such as the
presence of hypertension, diabetes, congestive heart failure, and vascular disease were compared
using chi-square. Continuous or interval variables (e.g., age) were compared and correlated.
Specific Aims
This study examined the following study aims:
AIM 1: Describe the patient demographics (e.g., age, gender, ethnicity, AF) of patients receiving
care in an outpatient cardiology clinic.
AIM 2: Describe the relationship between the dependent variable (AF) and independent
variables (e.g., BMI) in patients receiving care in an outpatient cardiology clinic.
AIM 3: Examine the frequency of AF diagnosis and the length of time to diagnosis in patients
implanted with an ICM receiving care in an outpatient cardiology clinic.
AIM 4: Examine provider patterns of treatment with OACs.
AIM 5: Investigate documented considerations to diagnose or rule out OSA in a group of
outpatient AF patients in a cardiology clinic.
Data collection plan. Once IRB approval was achieved, the data were de-identified to
be compliant with Health Insurance Portability and Accountability Act (HIPPA) regulations.

The database was password protected and documentation, including the codebook, was locked in
a drawer in the researcher’s office. All data will be destroyed 10 years after data collection.
Patients with suspected AF with ICM between June 2014 and December 2018 were included in
this convivence sample. At the time of this study, AF lasting 5 minutes or longer was associated
with a significantly-increased risk for stroke or systemic embolism in patients with a pacemaker
(Healey, Connolly, Gold et al. 2012); therefore, AF episodes longer than 6 minutes was used to
determine an episode. After the patient was diagnosed with AF, the cardiologist or cardiology
NP used the instruments to stratify the risk for stroke and bleeding. If the CHA2DS2-VASc score
was greater than or equal to 2 and the HAS-BLED score was less than 3, the patient was
educated on embolic and bleeding risk and joint decision was made to start an OAC or continue
current treatment. Routine education was given to the patient at that time discussing the risks for
stroke and bleeding as a standard procedure.
Data Analysis
Statistical analysis was conducted using Microsoft Excel© and SPSS (Version 24). A
power analysis using G*Power (Faul, 2014) suggested that the minimum number of patients
needed for the study was 200 with a moderate effect size .20 and an alpha of .05 for a two-tailed
test. Descriptive statistics were used for demographics information with means, standard
deviations, medians, skewness, and kurtosis, where appropriate. Pearson r and Spearman rho
correlations were used to examine the relationships between ordinal and interval data. Chi
square was used to test the frequencies between categorical variables. Study outcomes were
compared with the incidence of AF in patients and previous symptoms, such as palpitations,
syncope, and cryptogenic stroke. Secondary outcomes included the provider’s response to AF
and in combination with the CHA2DS2-VASc and HAS-BLED scores.

Study Timeline
Three months were required for IRB approval. Subsequently, the collection of data was
done over 6 months.
Theoretical Model
The Quality Health Outcomes Model is the conceptual framework guiding this study
(Figure 1). This model helps evaluate and compare the quality that a system places on their
subjects (Mitchell, Ferketich, & Jennings, 1998). The model evaluates quality improvement and
outcomes management through interventions within the system and the client (Mitchell et al).
Through the Quality Health Outcomes Model, the study’s conceptual framework works with the
independent variables of patient demographics and the ICM. The dependent variables are the
prescription of Nursing Implications

Figure 1. Quality health outcomes model. Adapted from “Quality health outcomes model.
American Academy of Nursing Expert Panel on Quality Health Care,” by P. H. Mitchell, S.
Ferketich, & B. M. Jennings, 1998, Image: The Journal of Nursing Scholarship, 30(1), p. 44.

Chapter 4
Results
The purpose of the study was to (a) describe patient demographics, (b) identify the
percentage of patients identified with a diagnosis of AF, and (c) identify the length of time in
days to diagnosis once an ICM was implanted into a cardiac patient. Additionally, this study
examined (d) whether there is an increase in frequency in OACs prescriptions with detection of
AF, and (e) whether there was an increase in frequency for OSA in patients with AF.
Inclusion criteria required that patients be adults aged 18 years or older, implanted with
an ICM, and a primary diagnosis among the following: AF management, cryptogenic stroke,
palpitations, suspected AF, syncope, or unknown reasons. Exclusion criteria eliminated those
patients who were already on anticoagulation for therapy for an indication other than AF and
those who were hemodynamically unstable. Patients diagnosed with valvular AF and patients
already enrolled in a clinical trial were also excluded. Furthermore, patients whose primary
language at home was other than English or Spanish were also excluded.
A portrayal of the sample population will be provided (Aim 1) along with descriptive
statistics for the dependent and independent variables. Findings for Aim 2-to-Aim 6 will follow.
Incidental findings will also be presented as possible future research.
Characteristics of the Sample
Aim 1. Describe the demographic information (e.g., age, gender, ethnicity, AF) for
patients receiving care in an outpatient cardiology clinic.
A total of 269 patients implanted with an ICM comprised the subjects of this research
study. A description of patients by gender and ethnicity are included in Table 1. Data about race
was not incorporated into the patient charts and, therefore, could not be extracted.

Table 1
Patient Information by Gender and Ethnicity
N

%

Male

116

43.1%

Female

153

56.9%

Hispanic

57

21.2%

Not Hispanic

40

14.9%

Undetermined

172

63.9%

Gender

Ethnicity

Participants in the study ranged from age 19-years to 93-years. The average age was
normally distributed (Skewness = -0.630; Kurtosis = 0.349). Height (Skewness = -0.721;
Kurtosis = 0.361) was also normally distributed but weight (Skewness = 0.966; Kurtosis = 1.108)
was slightly leptokurtic and BMI was both positively skewed and leptokurtic (Skewness = 1.018;
Kurtosis = 1.308). Table 2 provides descriptive detail about characteristics of these continuous
variables.

Table 2
Patient Characteristics (with Normal Distribution)
N

M

SD

Height (inches)

212

64.90

4.092

Weight (lbs)

210

176.93

47.718

BMI

207

29.17

6.143

Age (years)

255

65.24

15.056

After demographic information was extracted, patient records were examined to reveal
the documented justification for patients receiving an ICM. Table 3 categorizes these underlying
conditions.
Table 3
Justification for Implant (N = 269)
N

%

AF Management

16

5.9%

Cryptogenic Stroke

53

19.7%

Palpitations

44

16.4%

Suspected AF

38

14.1%

Syncope

89

33.1%

Unknown

29

10.7

The number of days from implant-to-AF detection (Skewness = 1.018; Kurtosis = 1.308)
was not normally distributed (i.e., slight, positive skew; leptokurtic). While the LINQ batterylife was limited to 3 years (1,096 days), one subject was an outlier and AF was detected over 3 ½

years after implant (1,289 days). Descriptive information about CHA2DS2-VASc and HASBLED scores, both ordinal scales, is also included on Table 4.
Table 4
Non-parametric Patient Measures
N

Range

Median

Mode

Days to detection

63

2, 1289

154

10, 14

CHA2DS2-VASc

218

0, 8

4

4

HAS-BLED

218

0, 5

3

3

Comparisons of Independent Variables to AF
Aim 2. Describe the relationship between the dependent variable (AF) and independent
variables (e.g., BMI) in patients receiving care in an outpatient cardiology clinic.
The second aim was to distinguish any differences in demographic information or
diagnostic testing for those subjects whose ICM detected AF. Significant differences were found
in age (MNo = 63.18, MYes = 71.76), CHA2DS2-VASc scores (MNo = 3.73, MYes = 4.33), and HASBLED scores (MNo = 2.56, MYes = 3.04). Height, weight, BMI, and Sleep Apnea Risk values were
not significantly different between the two groups. See Table 5 for detailed information.

Table 5
Significant Differences between Demographic/Diagnostic Information and AF Detection
Variable
Age
CHA2DS2-VASc
HAS-BLED

Detect AF
No
Yes
No
Yes
No
Yes

N
194
61
166
52
166
52

M
63.18
71.76
3.73
4.33
2.56
3.04

t
3.995***

p
<.001

2.178*

.03

2.593**

.01

Note. * p < .05; ** p < .01; *** p < .001.
Next, for subjects whose ICM identified AF, an ANOVA was performed to see if the
reason for implant differed among the continuous demographic and diagnostic variables. For age
and reason for ICM, patients with palpitations (M = 56.9 years) were significantly younger than
patients with suspected AF (M = 69.33 years).
The number of days reported to detect AF was significant by reason for the implant in the
overall model; however, a Scheffé post-hoc test failed to identify any specific variable difference
(range from 57.75 days for AF management to 387.53 days for syncope). Table 6 summarizes
these results.
Table 6
Differences in Demographics by Reason for Implant
df

F

p

BMI

4, 184

1.123

.347

Age

4, 226

3.929**

.004

Detect Days

4, 58

3.287*

.017

Note. * p < .05; ** p < .01; *** p < .001.
For other demographic variables, there was no difference in detection days between
genders (males 25/116, females 38/153). While there were no differences between ethnicities or

BMI and detection days, patients with suspected AF had a significantly higher frequency of AF
detected by the ICM (χ2 = 25.920, p < .001).
Assessing Time Needed to Diagnose AF
Aim 3. Examine the frequency of AF diagnosis and the length of time to diagnosis in
patients implanted with an ICM receiving care in an outpatient cardiology clinic.
The third aim examined the length of time (days) to diagnosis. Detection of AF occurred
in 63 of the 269 subjects (23.4%) in this study. The days needed to detect were then compared to
standard methods of monitoring patients to see the capture rate of AF detection. The median
detection days was 154. Detection days ranged from 2 days to 1,289 days. Figure 2 displays
these results.

Figure 2. Number of days to detect AF with ICM compared with traditional monitors.
Other type of arrythmias were also captured by the LINQ device. These rhythms are
included in Table 7.
Table 7

Arrythmia Symptoms (N = 210)
N

%

Atrial Tachycardia (A Tach)

17

28.8

Ventricular Tachycardia (V Tach)

4

6.8

Supraventricular Tachycardia (SVT)

21

35.6

Premature Ventricular Contractions (PVC)

9

15.3

Bradycardia

8

13.6

Treatment with Oral Anti-Coagulants (OACs)
Aim 4. Examine provider patterns of treatment with OACs.
The fourth aim examined whether an increase in frequency occurred in patients
prescribed OACs and detection of AF. Out of the 63 patients (23.4%) where AF was detected,
52.4% of those detected were on OACs (i.e., Eliquis, Xarelto). There was a significantly higher
frequency of patients with detected AF on Eliquis and Xarelto (χ2 = 58.462, p < .001). The
average age of patients on Eliquis was 77-years and on Xarelto was 68 years. Descriptive
information about Aim 4 can be found in Table 8.

Table 8
Oral Anticoagulant Medications (N = 215)
N
(All)
34

%
All
12.6

N
(Detected)
4

%
(Detected)
6.3

Eliquis

20

7.4

15

23.8

Xarelto

33

12.3

18

28.6

None

128

47.6

15

23.8

Missing

54

20.1

9

14.3

Antiplatelet

When patients were risk-stratified, two scoring tools are used to determine embolic
(stroke) risk. For the instrument, CHA2DS2-VASc scores range from 0 to 8. The median
CHA2DS2-VASc score of the sample was 4. Likewise, the HAS-BLED scores range from 0 to 8
and this sample of patients had a median score of 3.
Obstructive Sleep Apnea (OSA) and AF
Aim 5. Investigate documented considerations to diagnose or rule out OSA in a group of
outpatient AF patients in a cardiology clinic.
The fifth aim was to determine whether there was an increased frequency of OSA for
patients with AF. For this assessment of OSA risk, the STOP-BANG tool was used. Detailed
results are presented in Table 9.

Table 9
Questionnaire Responses for STOP-BANG

Snore
Fatigue
Breath
Hypertension
BMI > 35 kg/m2
Age > 50
Neck > 17” (Male)
> 16” (Female)
Gender

Yes
(% of Total)
65
(24.2)
63
(23.4)
33
(12.3)
180
(66.9)
33
(12.3)
193
(71.7)
7
(2.6)
Male
116
(43.1)

No
(% of Total)
36
(13.4)
38
(14.1)
68
(25.3)
39
(14.5)
183
(68.0)
29
(13.1)
11
(4.1)
Female
153
(56.9)

Missing
(% of Total)
168
(62.5)
168
(62.5)
168
(62.5)
50
(18.6)
53
(19.7)
47
(17.5)
251
(93.4)

% of Yes to
Known (Valid
%)
64.4%
62.4%
32.7%
82.2%
15.1%
86.9%
38.9%

The total score of the STOP-BANG assessment is used to assess the risk categories of
OSA. This instrument was administered through multiple attempts at telephone contact. A total
of 99 patients could be reached to complete this 8-question survey. Simple scoring can establish
Low and Intermediate risks but High risk identification follows an algorithm outlined on p. 11.
Table 10 shows the distribution of subjects by risk category.

Table 10
Assignment of Risk Score (N = 99)
Risk Category (Score)

N

%

Low (0-2)

19

7.1%

Intermediate (3-4)

18

6.7%

High (see algorithm)

62

23.0%

Total

99

36.8%

Missing data

170

63.2%

To assess whether correlations existed between the STOP-BANG other data gathered in
this study, Pearson r and Spearman rho calculations were performed based on the characteristics
of each variable. There was a positive correlation between STOP-BANG sleep apnea scores and
BMI (ρ = .425, p < .001). This could suggest that the higher one’s weight, the more likely that
patient was at risk for OSA.
In addition, there was an inverse correlation between STOP-BANG sleep apnea scores
and AF detect days (ρ = -.504, p > .01). This suggests that, the higher the STOP-BANG score,
the fewer days pass before AF detection with the ICM.
Incidental Findings
A positive correlation was identified between the CHA2DS2-VASc scores and HASBLED scores (r = .701, p < .001). Specifically, as CHA2DS2-VASc scores increased, so did the
HAS-BLED scores.
Several significant correlations were seen between age and other variables collected in
this study. Age had a significant, moderate, positive correlation with the CHA2DS2-VASc scores
(r = .523, p < .001). Age was also moderately and positively correlated to the days needed to

detect AF (ρ = .449, p < .001). Other significant and non-significant correlations are presented in
Table 11
Table 11
Pearson r and Spearman rho (†) Correlations
CHA2DS2-VASc

HAS-BLED

BMI†

Age

Detect Days†

CHA2DS2-VASc

1

HAS-BLED

.723***

1

Age

.558***

.567***

1

BMI†

-.255***

-.189**

-.405***

1

Detect Days†

.255

.063

.449***

-.240

1

STOP-BANG

.071

.241*

-.029

.425***

-.504**

Note. † Spearman rho. * p < .05; ** p < .01; *** p < .001.

Another incidental finding was uncovered among the limited number of OSA
assessments. With documented OSA risk, information was extracted from the patient’s chart
about their OSA diagnosis, referral, and follow-up (Table 12).
Table 12
Patients At-Risk for Sleep Apnea
N

%

Diagnosed with sleep disorder

16

5.9

Sleep study ordered

2

0.7

Negative per sleep study

3

1.1

248

92.3

Unknown or Missing

Limitations
Data were collected between the hours of 8:00 a.m. and 5:00 p.m., Monday thru Friday.
Another limitation was that the data were collected in a single office; therefore, this study
population might not be generalizable to other settings. Potential errors with medical records
and data entry could have occurred with data input. Potential confounders were rapid cardiac
rhythms that could have been misdiagnosed and medical conditions that might have developed
prior to implant. Some patients failed with follow up by not connecting their monitors to the
wall-unit transmitter or by not reconnecting or reprogramming the monitor when an error
occurred. Other patients may have decided to or needed a change of cardiologists due to
insurance or preference. Future studies should be designed to capture these potentially
significant confounders.
Summary
This chapter presented the results of the data analysis for this study. Each of the five
research aims were outlined and interpreted. Incidental findings were also presented to possibly
guide future studies. The limitations experienced in data collection were also addressed.

Chapter 5
Conclusions
Discussion of Findings
This research addressed five areas of inquiry examining the available data on 269 patients
who received an ICM and the potential assessment of AF. The first aim of this retrospective
study described the patient demographics. The second aim stratified groups (e.g., reason for
implant) and compared them with the length of time needed to identify AF. The third aim
analyzed the length of time in days to diagnosis. Aim 4 examined the frequency of OAC
prescriptions with the detection of AF. The fifth aim scrutinized AF detection in patients who
were also at risk or had been identified as having OSA. Finally, significant observations not
incorporated into the five research aims were presented as evidence of the need for future
research.
This chapter will discuss and summarize the research design, method, data analysis, and
overall results. Nursing implications will also be addressed.
This study provided profuse amounts of scientific knowledge regarding patients who
received an ICM in a southern California cardiology outpatient clinic comparing and contrasting
those treated for AF and those not yet diagnosed. This retrospective database study design was
performed in a setting that routinely-collected data on patients with ICMs implanted from June 1,
2014 through December 31, 2018. The sample had a similar distribution of age groups for males
and females, but this population contained 37 more female patients. Information about race and
ethnicity was not routinely captured in the existing database. A description of the
average/median patient would be female, 5’5” in height, and 180 pounds in weight.

The incidence of AF using an ICM (i.e., Medtronic LINQ) device in an outpatient clinic
was 23.4%, similar to national studies stating that longer monitoring of cardiac rhythms
increased the diagnosis of arrythmias. Only 12.7% of detected AF occurred before 14 days, the
maximum amount of time available through the use of other, traditional monitors in standard
use; therefore, a surprising 87.3% of detected arrythmias found with the ICM could have
remained unidentified. To recap, shorter monitoring devices have arrythmia-detection
capabilities up to 2 days (Holter monitor) or 7-14 days (Telemetry, Zio Patch), a disappointing
statistic considering that the median number of days needed to detect AF in this study was 154
days (M = 270 days). For monitors that had been implanted within the last 18 months, 30.17%
detected AF. This equals the CRYSTAL AF study (Sanna et al., 2014); however, the CRYSTAL
AF study only examined patients with cryptogenic stroke and suspected AF and the present study
included multiple symptomology, including palpitations and syncope.
The ICM monitors are a useful way to identify arrythmias without the patient being
responsible for the maintenance and control the device. The automatic download by wireless
function decreases data entry error.
Intracardiac monitors are also useful in assisting with stroke-risk stratification and
bleeding risks among patients diagnosed with AF. Previously, AF patients at risk for stroke were
prescribed warfarin; however, the potential benefit of OACs was found to significantly improve
the composite of stroke or systemic embolic events by 19% when compared with warfarin (Hart,
Pearce, & Aguilar, 2007). Presently, OACs are used more frequently, particularly after the
PINNACLE trial (Hsu et al., 2016). In the PINNACLE Trial, less than 55% of patients who
were considered at moderate-to-high risk for stroke received OACs; this study found that 63.5%
of those patients were treated with OACs. This increase in treatment for this study may be due

in part to the new OACs. The number of patients who are not on OACs could be explained by
the WATCHMAN procedure or fall risk, both contraindications for OAC use. These factors
were not taken into account for not prescribing OACS in this patient population. During the
PINNACLE trial, warfarin was the only option for anticoagulation. Newer anticoagulants have
lower bleeding risk profiles; are easier to prescribe; simpler to manage, with no weekly blood
draws; and do not interfere with foods or most other medications. This may provide some
security in prescribing habits by clinicians. These factors were not taken into account for not
prescribing OACS in this patient population.
Future Studies
Future studies should examine links between OSA and the detection of AF. With an
inadequate number of responders to the STOP-BANG instrument (n no = 74, n yes = 25),
statistical significance could not be achieved in this study but the data were trending toward a
higher score on the STOP-BANG score in those patients diagnosed with AF. As the STOPBANG scores were normally distributed (M = 3.93, Median = 4, Mode = 4, SD = 1.599,
Skewness = -.188, Kurtosis = -.214), a comparison was made between patients diagnosed with
AF and those who did not have documented AF. The comparison between these groups was not
statistically significant, but warrants further examination (Figure 3).

Figure 3. Comparison of STOP-BANG scores between AF and non-AF patients.
Future studies should examine OSA and AF detection in larger sample size and multiple
locations. In this study, responses were captured by phoning each patient 1-to-3 times to answer
a subjective questionnaire, STOP-BANG. As STOP-BANG scores increased, the number of
days needed to detect AF was lower. Most patients in this research study were at moderately
high risk for OSA (Median = 4). BMI was not significant in relation to AF, but presents another
factor worthy of further examination.
Implications for Nursing
This study reveals pivotal points for focused research with AF. With new, longer
monitoring capabilities, the identification of disease and decrease in morbidity for AF patients is
more promising. This research study aligns with larger studies performed (Hsu et al, 2016).
Continued research with AF should be conducted to provide adequate information for the
implementation of tailored intervention programs that encourage extended monitoring devices,
encourage standardized protocols and guidelines for arrythmias management, foster and educate
policymakers, and address insurance loopholes that require shorter monitor devices. Prevention

of major comorbidities (e.g., thromboembolic events) are also important and possible with an
increase in identifying AF. With an increase in the cost of rehabilitation and level of care needed
for patients after these events, the benefit from identifying this cardia arrythmia sooner will save
health care costs and improve quality of life. The adoption and utilization of health information
technology is still relatively low among patients with chronic disease.
Conclusion
As evidenced by this study, most patients would not have been identified with AF
utilizing the shorter-duration monitoring devices typically used as the first line of treatment.
Longer monitoring capabilities promise early identification of disease and reduction in morbidity
for AF patients and will also increase awareness and aid in decision-making when seeing patients
in the outpatient setting. The prevention of major comorbidities such as thromboembolic events
are also possible with an increase in identifying AF. The cost-avoidance of rehabilitative care
for AF sequela may be realized by identifying this cardia arrythmia sooner.
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